论文部分内容阅读
碳酸酐酶抑制剂(CAI)在长期治疗青光眼患者过程中证明有效,但常因付作用而受到限制,例如:胃肠道不适,不舒服,厌食,体重减轻,感觉异常,性欲丧失等。此外,应用CAI还伴随着某种二氧化碳代谢的改变,使体内CO_2的输送受到损害,导致身体组织和肺泡之间二氧化碳的梯度差(gradient)增大,二氧化碳在体内潴留。大多数病人,可以通过增加肺泡的通气量,建立一个新的CO_2产生、消耗的稳定状态,来调节CAI所引起的这种改变的。然而,组织和肺泡间的CO_2梯度差增大以及伴随或不伴随明显的酸中毒,对某些病人会带来潜在危险,特
Carbonic anhydrase inhibitors (CAIs) have been shown to be effective in the long-term treatment of patients with glaucoma, but are often limited by pay-offs such as gastro-intestinal discomfort, discomfort, anorexia, weight loss, sensory abnormalities, loss of libido and the like. In addition, the use of CAI is accompanied by some change in carbon dioxide metabolism, which impairs the delivery of CO 2 in the body, leads to an increased gradient of carbon dioxide between body tissues and alveoli, and carbon dioxide retention in the body. Most patients can regulate this change caused by CAI by increasing alveolar ventilation, establishing a new steady state of CO 2 production and consumption. However, an increased CO 2 gradient between tissues and alveoli, with or without significant acidosis, poses a potential hazard to some patients, particularly